Vera Therapeutics' Drug to Reduce Proteinuria Gets FDA Approval

MT Newswires Live07-08

Vera Therapeutics' (VERA) Trutakna has been approved to reduce proteinuria in adults with primary immunoglobulin A nephropathy, the US Food and Drug Administration said in a Tuesday statement.

Trutakna is injected subcutaneously once weekly, the FDA said.

IgA nephropathy is a serious kidney disease that occurs when an abnormal form of an immunoglobulin A antibody builds up in the kidneys, causing kidney inflammation and damage, it said.

The drug also received priority review and breakthrough therapy designation for the indication, according to the FDA.

Shares were up over 6% in afternoon trading.

Price: 42.89, Change: +2.76, Percent Change: +6.88

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2649931640?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-08 00:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2649931640","market":"fut","top_or_hot":-1,"title":"Vera Therapeutics' Drug to Reduce Proteinuria Gets FDA Approval","media":"MT Newswires Live","content":"<html><body><p> Vera <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' (VERA) Trutakna has been approved to reduce proteinuria in adults with primary immunoglobulin A nephropathy, the US Food and Drug Administration said in a Tuesday statement.</p><p>Trutakna is injected subcutaneously once weekly, the FDA said.</p><p>IgA nephropathy is a serious kidney disease that occurs when an abnormal form of an immunoglobulin A antibody builds up in the kidneys, causing kidney inflammation and damage, it said.</p><p>The drug also received priority review and breakthrough therapy designation for the indication, according to the FDA.</p><p>Shares were up over 6% in afternoon trading.</p><p>Price: 42.89, Change: +2.76, Percent Change: +6.88</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vera Therapeutics' Drug to Reduce Proteinuria Gets FDA Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVera Therapeutics' Drug to Reduce Proteinuria Gets FDA Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-08 00:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Vera <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' (VERA) Trutakna has been approved to reduce proteinuria in adults with primary immunoglobulin A nephropathy, the US Food and Drug Administration said in a Tuesday statement.</p><p>Trutakna is injected subcutaneously once weekly, the FDA said.</p><p>IgA nephropathy is a serious kidney disease that occurs when an abnormal form of an immunoglobulin A antibody builds up in the kidneys, causing kidney inflammation and damage, it said.</p><p>The drug also received priority review and breakthrough therapy designation for the indication, according to the FDA.</p><p>Shares were up over 6% in afternoon trading.</p><p>Price: 42.89, Change: +2.76, Percent Change: +6.88</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2324357040.USD","symbol_name":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2649931640","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2649931640","pubTimestamp":1783443137,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Vera Therapeutics'  Trutakna has been approved to reduce proteinuria in adults with primary immunoglobulin A nephropathy, the US Food and Drug Administration said in a Tuesday statement.Trutakna is injected subcutaneously once weekly, the FDA said.IgA nephropathy is a serious kidney disease that occurs when an abnormal form of an immunoglobulin A antibody builds up in the kidneys, causing kidney inflammation and damage, it said.The drug also received priority review and breakthrough therapy designation for the indication, according to the FDA.Shares were up over 6% in afternoon trading.Price: 42.89, Change: +2.76, Percent Change: +6.88","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","BK4139":"生物科技","VERA":"Vera Therapeutics, Inc.","BK4539":"次新股","LABU":"三倍做多标普生物-Direxion","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"Vera Therapeutics减少蛋白尿药物获得FDA批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VERA":1.5,"LABU":1.5},"content_text":"Vera Therapeutics' (VERA) Trutakna has been approved to reduce proteinuria in adults with primary immunoglobulin A nephropathy, the US Food and Drug Administration said in a Tuesday statement.Trutakna is injected subcutaneously once weekly, the FDA said.IgA nephropathy is a serious kidney disease that occurs when an abnormal form of an immunoglobulin A antibody builds up in the kidneys, causing kidney inflammation and damage, it said.The drug also received priority review and breakthrough therapy designation for the indication, according to the FDA.Shares were up over 6% in afternoon trading.Price: 42.89, Change: +2.76, Percent Change: +6.88","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2649931640","isCrawlerRequest":true}